TABLE 2.

Pharmacological Treatment Options in the Setting of Severe Insulin Resistance

Medication ClassA1C Lowering*Hypoglycemia RiskWeight EffectEase of UseTolerability IssuesRelative Cost
Treatment options that have been evaluated in patients with severe insulin resistance
GLP-1 receptor agonists↓↓←→↓↓Subcutaneous; once daily or once weeklyNausea, vomiting$$$
  • * Additional A1C lowering in previously treated patients;= 0.5–1%, ↓↓ = 1–1.5%, ↓↓↓ = 1.5–2%.

  • Relative cost per 30-day supply; $ = <$100, $$ = $100–299, $$$ = $300–750, $$$$ = >$750 based on average wholesale price (54).